Primary Outcomes:

Primary Outcome 1 - Measure: Safety and tolerability of SQ3370, including determination of the maximum tolerated dose and the recommended Phase 2 dose.

Primary Outcome 1 - Time Frame: 35 Days

Condition:

• Cancer

Eligibility

Criteria:
Inclusion Criteria:

- Diagnosis of an advanced local or metastatic solid tumor

- Adequate hematologic, hepatic, renal, and coagulation function

- Tumor is the type where published clinical data would suggest that anthracyclines have
cytotoxic activity

Exclusion Criteria:

- Prior exposure to 300 mg/m^2 of Dox HCl or DOXIL / CAELYX ® or 600 mg/m^2 of
Epirubicin HCl

- CHF, severe myocardial insufficiency, or cardiac arrhythmia

- Any of the following within 28 days prior to Cycle 1 Day 1:

- Major surgery, as defined by the Investigator

- Radiotherapy

- Chemotherapy, immunotherapy and/or anticancer therapy (except for small molecule
kinase inhibitors, which are 6 elimination half-lives)

- Currently enrolled in or discontinued from a clinical study involving an
investigational agent or non-approved use of a drug or device, or concurrently
enrolled in any other type of medical research judged not to be scientifically or
medically compatible with this study
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No